Selecting patients for randomized trials: A systematic approach based on risk group

Trials

Volumn 7, Issue , 2006, Pages

  Vickers, Andrew J ^a   Kramer, Barry S ^b   Baker, Stuart G ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL RESEARCH; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SELECTION; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; SAMPLE SIZE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; STATISTICAL ANALYSIS;

EID: 33750219137     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-7-30     Document Type: Article

References (9)

1. Gohagan JK: The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Controlled Clinical Trials 2000, 21(6, Supplement 1):249S.
2. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB: Variations in Lung Cancer Risk Among Smokers. J Natl Cancer Inst 2003, 95(6):470-478.
3. Baker S, Kramer B, Corle D: The fallacy of enrolling only highrisk subjects in cancer prevention trials: Is there a "free lunch"? BMC Medical Research Methodology 2004, 4(1):24.
4. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJ, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW: Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. J Clin Oncol 2005, 23(28):7005-7012.
5. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ: When should an effective treatment be used?: Derivation of the threshold number needed to treat and the minimum event rate for treatment. Journal of Clinical Epidemiology 2001, 54(3):253.
6. Baker SG, Heidenberger K: Choosing sample sizes to maximize expected health benefits subject to a constraint on total trial costs. Med Decis Making 1989, 9(1):14-25.
7. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM: Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application. J Natl Cancer Inst 2005, 97(10):715-723.
8. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol 2004, 22(10):1797-1806.
9. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SAA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JAE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D, the Women's Health Initiative I: Calcium plus Vitamin D Supplementation and the Risk of Fractures. N Engl J Med 2006, 354(7):669-683.